Who raised $140 million to reach unicorn status and could this be the end of Start-Up Nation?

CTech Daily Roundup: Israeli companies on Wall Street reach historic $300 billion market cap landmark

CTech 22:1117.06.21
Israeli companies on Wall Street reach historic $300 billion market cap landmark. WalkMe became the 85th Israeli company to currently be traded on Nasdaq and NYSE. The market cap of blue-and-white companies on Wall Street has surged by $100 billion since the start of the year. Read more


Claroty secures unicorn status with $140 million funding round. The Israeli industrial cybersecurity company reached a valuation of $1 billion thanks to 133% year-over-year growth in new annual recurring revenue. Read more


Agritech. Photo: Nissan Agritech. Photo: Nissan


Banking-as-a-Service startup Unit announces $51 million Series B led by Accel. Israeli startup launches Unit Go to allow companies and fintechs to build banking products in minutes. Read more


Align Technology prepares to hire 150 Israelis in 2021. The company intends to add to its 500-strong team of employees in the country. Read more


Spotlight | Feelit's nanotech sticker is awaiting in the pipeline. Israeli startup Feelit's sensor-sticker can monitor pipes, valves and steam traps. “You can think of our sensors as electronic skin," says CTO Meital Segev-Bar. Read more


Analysis | Is this the end of Start-Up Nation? Hi-tech may have helped Israel out of the coronavirus crisis, but the sector is also suffering from severe problems. The Israel Innovation Authority's annual Innovation Report warns that if government policy doesn't change, local tech could steam ahead and detach itself from the rest of the economy. Read more


Foodtech and agritech startup studio launched in Galilee. "Our goal is to see at least three startups that raise between $2-4 million every year,” said Erel Margalit, Chairman of JVP, which is behind Startup City.Galil. Read more


Opinion | How can startups leverage controversial FDA approval for Alzheimer’s drug? The decision to approve Biogen's Alzheimer’s drug signifies a watershed moment for neurology, highlighting an unprecedented opportunity for neurology-focused startups. Read more